Roche’s Stealth Bomber Blocks Biocon/Mylan From Using Herceptin Name In India
This article was originally published in PharmAsia News
Executive Summary
After withdrawing its trastuzumab patents last year in India, Roche has shocked stakeholders by obtaining a restraining order from an Indian court after questioning the approval process for biosimilars to be marketed by Biocon and Mylan.